MedElevator
Войти в исследования Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
Evaluation of Tissue from Patients with Prostate Cancer Identifies B7-H3 as an Androgen-Regulated, Broadly Expressed, Combinatorial Therapeutic Target.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sharma Shivang, Mundhara Nikita, Tekoglu Emirhan, Amaral Adrianna, Gu Pan, Luo Jun, Xie Sean, Konchou Morelle Meegane, Pepra-Ameyaw Patience, De Marzo Angelo M, Brennen W Nathaniel, Baraban Ezra G, Lotan Tamara L, Lack Nathan A, Shenderov Eugene
Аннотация
PURPOSE: Advanced prostate cancer management suffers from therapeutic resistance due to naturally transient or androgen receptor (AR)-dependent expression of clinically actionable surface targets. We aimed to identify the most promising clinically relevant prostate cancer targets using RNA and protein expression levels across the prostate cancer continuum-hormone-sensitive, castration-resistant, neuroendocrine, and "double-negative" prostate cancer.
EXPERIMENTAL DESIGN: We performed integration of a large single-cell transcriptomics atlas (JHU-PANORAMA, ∼1 million cells and 213 patients) and patient-derived xenograft models for the systematic investigation of the clinically relevant surfaceome, followed by proteomic validation on patient samples and mechanistic investigations on prostate cancer cell lines and patient samples.
RESULTS: B7 homolog 3 (B7-H3) was found to be the most uniformly expressed across the entire prostate cancer continuum. JHU-PANORAMA is made available for interactive visualization as an R Shiny web app. Further mitigation of therapeutic resistance is proposed through a systematic framework for bispecific antibody design, in which B7-H3 demonstrates high combinatorial scores with TROP-2, NECTIN1, KLK2, and NECTIN4. B7-H3 was also shown to be negatively regulated by AR and synergistically inhibit tumor growth when combined with androgen inhibition.
CONCLUSIONS: B7-H3 demonstrates low interpatient and intratumoral heterogeneity, with significant synergistic effects in combination with AR inhibition. These properties could uniquely position B7-H3 as a broad-spectrum therapeutic target, with the potential to combine B7-H3 based therapeutics with standard androgen deprivation therapy for synergistic effects to overcome therapeutic resistance across the prostate cancer disease continuum. See related article by Makovec et al., p. 3381.
EXPERIMENTAL DESIGN: We performed integration of a large single-cell transcriptomics atlas (JHU-PANORAMA, ∼1 million cells and 213 patients) and patient-derived xenograft models for the systematic investigation of the clinically relevant surfaceome, followed by proteomic validation on patient samples and mechanistic investigations on prostate cancer cell lines and patient samples.
RESULTS: B7 homolog 3 (B7-H3) was found to be the most uniformly expressed across the entire prostate cancer continuum. JHU-PANORAMA is made available for interactive visualization as an R Shiny web app. Further mitigation of therapeutic resistance is proposed through a systematic framework for bispecific antibody design, in which B7-H3 demonstrates high combinatorial scores with TROP-2, NECTIN1, KLK2, and NECTIN4. B7-H3 was also shown to be negatively regulated by AR and synergistically inhibit tumor growth when combined with androgen inhibition.
CONCLUSIONS: B7-H3 demonstrates low interpatient and intratumoral heterogeneity, with significant synergistic effects in combination with AR inhibition. These properties could uniquely position B7-H3 as a broad-spectrum therapeutic target, with the potential to combine B7-H3 based therapeutics with standard androgen deprivation therapy for synergistic effects to overcome therapeutic resistance across the prostate cancer disease continuum. See related article by Makovec et al., p. 3381.